Skip to main content

Table 1 Clinical-Pathological features of HM, HM-like and non-HM groups

From: An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

  

HM

(n = 78)

HM-like

(n = 41)

Non-HM

(n = 401)

P value

Stage

I

14 (17.9%)

10 (24.4%)

62 (15.5%)

NS

II

45 (57.7%)

16 (39.0%)

123 (30.9%)

***

III

14 (17.9%)

13 (31.7%)

125 (31.2%)

*

IV

3 (3.8%)

1 (2.4%)

72 (18.0%)

***

No data

2 (2.6%)

1 (2.4%)

19 (4.7%)

***

Location

Ascending

50 (64.1%)

21 (51.2%)

115 (28.7%)

***

Transverse

10 (12.8%)

8 (19.5%)

16 (4.0%)

***

Descending

12 (15.4%)

11 (26.8%)

253 (63.1%)

***

No data

6 (7.7%)

1 (2.4%)

17 (4.2%)

 

Mutational Burden

Median of mutations/Megabase

44.9

3.9

3.5

 

MSI-status

MSI-H

61 (78.2%)

6 (14.6%)

3 (0.7%)

***

MSS/MSI-L

11 (14.1%)

34 (82.9%)

377 (94.0%)

***

 

Indeterminate

6 (7.7%)

1 (2.4%)

21 (5.2%)

Pol-ε exonuclease domain mutation

 

15 (19.2%)

0

0